Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · as published 2026-01-23 View official record Methodology

Covered recipient · General Payments record

WAYNE CAMPBELL

Allopathic & Osteopathic Physicians Internal Medicine

NPI
1417926577
CMS profile
245192
Location
CRESTVIEW, FL

General Payments · PY2018–2024

$4,453.38

  • Reported across 115 records
  • CMS publication 2026-01-23

Latest program year · PY2024

$759.36

16 records · 0 disputed

Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.

How these totals are calculated
  • The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
  • Methodology & Data — sourcing, labeling, and limitations.

By nature of payment

PY2024 · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $759.36 16

By paying entity

PY2024 · sorted by reported total

Paying entityAmountRecords
Acerta Pharma LLC $339.17 4
Novo Nordisk AS $206.42 10
BOSTON SCIENTIFIC CORPORATION $144.37 1
Lilly USA, LLC $69.40 1

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2018 $857.57 38
PY2019 $924.23 37
PY2020 $393.48 8
PY2021 $630.14 6
PY2022 $386.62 5
PY2023 $501.98 5
PY2024 $759.36 16

Payment records · PY2024 (16)

Sorted by paying entity, then date · as published by CMS

Program year 2024 201820192020202120222023 Record-level detail is published for PY2024; earlier years are summarised in “By program year”.
Paying entity Amount Date Nature of payment Dispute status Published Record ID Source
AstraZeneca Pharmaceuticals LP $96.30 03/07/2024 Food and Beverage Undisputed 01/23/2026 1104246205 CMS
AstraZeneca Pharmaceuticals LP $15.06 07/17/2024 Food and Beverage Undisputed 01/23/2026 1105823765 CMS
AstraZeneca Pharmaceuticals LP $106.57 08/20/2024 Food and Beverage Undisputed 01/23/2026 1105626139 CMS
AstraZeneca Pharmaceuticals LP $121.24 10/30/2024 Food and Beverage Undisputed 01/23/2026 1105533838 CMS
Boston Scientific Corporation $144.37 10/03/2024 Food and Beverage Undisputed 01/23/2026 1092414460 CMS
Lilly USA, LLC $69.40 03/14/2024 Food and Beverage Undisputed 01/23/2026 1135480353 CMS
Novo Nordisk Inc $10.74 01/12/2024 Food and Beverage Undisputed 01/23/2026 1097244839 CMS
Novo Nordisk Inc $10.54 01/30/2024 Food and Beverage Undisputed 01/23/2026 1097340905 CMS
Novo Nordisk Inc $121.24 02/29/2024 Food and Beverage Undisputed 01/23/2026 1096566962 CMS
Novo Nordisk Inc $13.58 03/15/2024 Food and Beverage Undisputed 01/23/2026 1097545200 CMS
Novo Nordisk Inc $7.54 04/11/2024 Food and Beverage Undisputed 01/23/2026 1097056874 CMS
Novo Nordisk Inc $14.34 04/18/2024 Food and Beverage Undisputed 01/23/2026 1097264220 CMS
Novo Nordisk Inc $7.27 05/08/2024 Food and Beverage Undisputed 01/23/2026 1097702028 CMS
Novo Nordisk Inc $6.63 08/15/2024 Food and Beverage Undisputed 01/23/2026 1097438700 CMS
Novo Nordisk Inc $6.56 09/04/2024 Food and Beverage Undisputed 01/23/2026 1097590435 CMS
Novo Nordisk Inc $7.98 12/19/2024 Food and Beverage Undisputed 01/23/2026 1097823241 CMS

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-01-23
Program years on this page
2018, 2019, 2020, 2021, 2022, 2023, 2024
Source files
Dataset page · Bulk file · PY2018 , PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024
Generated from
OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.